报告人简介：王伊副研究员本科于2006年毕业于中国科学技术大学生命科学学院，随后在美国Duke University生物化学系学习并取得博士学位。他在Duke就读期间参与了新型脑卒中治疗药物CN-105的研发工作。回国后，王伊博士先后在中科院生物物理所、军事医学研究院、蛋白质药物国家工程研究中心工作，并于2018年10月创立Excerene Biosciences Co. Ltd, 基于干细胞外泌体技术和AI药物设计技术开发新型治疗药物。目前已有两个新药品种获得IND，研究发表在《JACS》、《Small》、《Sensors and Actuators B》等期刊上。
报告简介: 1) CN-105 is a clinical-stage neuroprotective drug that is being evaluated in several clinical trials of intracranial hemorrhage and ischemic stroke in China, US and Singapore. The drug was initially designed as an ApoE-mimetic peptide, while its true mechanism of action remains elusive. Not until recently have we zeroed in the molecular target of CN-105. Here we recapitulate a 7-yr target identification study of CN-105, and share the lessons learned along the way. 2) Extracellular vesicle (EV), especially exosome, is a unique type of natural nanoparticle that posesses great promises in both targeted drug delivery and cell-free cell therapy. It has become a field of intensive research and a hot spot for venture capitals. One limitation of current technology of therapeutic exosome is a lack of scalability and compatibility with current GMP production facility of biological drugs. At Excerene Biosciences, we are striving to develop a scalable and GMP-compatible manufacture process of therapeutic exosomes from both cell culture supernatant and bovine milk. Here we report current progress and challenges in this field.